Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1
Uzpruvo Makes Inroads Into Ustekinumab Market But Generics Growth Muted
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
